Skip to main content

Advertisement

SpringerLink
Log in

Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings

  • Clinical Study - patient studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Peripheral neuropathy (PN) is one of the most common and dose-limiting side effects of paclitaxel, a chemiotherapeutic drug of proven efficacy in various tumours. We investigated the pathophysiological features of the PN and the temporal relationships between the development of the symptoms and signs associated with paclitaxel administration in two groups of patients with breast cancer: group A received paclitaxel alone (total cumulative dose range: 950–2,475 mg/m2), and group B paclitaxel and adriamycin (total cumulative dose range: 700–2,800 mg/m2). A codified assessment scoring clinical sensory and motor functions according to the Common Toxicity Scale and neurophysiological measurements were made before treatment, after the third and sixth cycles, and at the end of therapy. A total neuropathy score (TNS) included selected clinical and neurophysiological parameters. Both positive and negative sensory and motor symptoms and signs of PN developed during therapy, the most common being painful paresthesias, global areflexia and distal weakess. The neurophysiological study showed an early onset, length-independent and progressive sensory defect, and delayed, distal and length-dependent motor deficits. The neuropathy progressed faster in group A than in group B but, after therapy, most of the patients were TNS grade 2 regardless of their group. The temporal relationships between the PN and paclitaxel were robustly characterised, and thus provide reference data and a model for testing the efficacy of drugs designed to provide neuroprotection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993) Neurotoxicity of Taxol. J Natl Cancer Inst Monogr (15):107–115

  2. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4 Suppl 3):1–15

    PubMed  CAS  Google Scholar 

  3. Masurovsky EB, Peterson ER, Crain SM, Horwitz SB (1983) Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol. Neuroscience 10(2):491–509

    Article  PubMed  CAS  Google Scholar 

  4. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35(3):304–311

    Article  PubMed  CAS  Google Scholar 

  5. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ (1995) Paclitaxel-induced neuropathy. Ann Oncol 6(5):489–494

    PubMed  CAS  Google Scholar 

  6. Postma TJ, Hoekman K, van Riel JM, Heimans JJ, Vermorken JB (1999) Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neurooncol 45(3):241–246

    Article  PubMed  CAS  Google Scholar 

  7. Chaudhry V, Corse AM, Freimer ML, Glass JD, Mellits ED, Kuncl RW et al (1994) Inter- and intraexaminer reliability of nerve conduction measurements in patients with diabetic neuropathy. Neurology 44(8):1459–1462

    PubMed  CAS  Google Scholar 

  8. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M et al (1999) Total neuropathy score: validation and reliability study. Neurology 53(8):1660–1664

    PubMed  CAS  Google Scholar 

  9. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F et al (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13(11):2688–2699

    PubMed  CAS  Google Scholar 

  10. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E et al (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87(15):1169–1175

    Article  PubMed  CAS  Google Scholar 

  11. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N et al (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75(5):1141–1150

    Article  PubMed  CAS  Google Scholar 

  12. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2001) Neurotoxicity associated with a regimen of carboplatin (AUC 5−6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 127(1):55–58

    Article  PubMed  CAS  Google Scholar 

  13. Markman M (2003) Managing taxane toxicities. Support Care Cancer 11(3):144–147

    PubMed  Google Scholar 

  14. Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J et al (1993) Overview of Taxol safety. J Natl Cancer Inst Monogr (15):131–139

  15. Pace A, Bove L, Aloe A, Nardi M, Pietrangeli A, Calabresi F et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18(2):73–79

    Article  PubMed  CAS  Google Scholar 

  16. Warner E (1995) Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 5(3):161–169

    Article  PubMed  Google Scholar 

  17. Scaioli V, Caraceni A, Martini C, Curzi S, Capri G, Luca G (2006) Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. J Neurooncol 77(1):79–87

    Article  PubMed  CAS  Google Scholar 

  18. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17

    Article  PubMed  CAS  Google Scholar 

  19. Cavaletti G, Tredici G, Braga M, Tazzari S (1995) Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133(1):64–72

    Article  PubMed  CAS  Google Scholar 

  20. Cavaletti G, Cavalletti E, Oggioni N, Sottani C, Minoia C, D’Incalci M et al (2000) Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 21(3):389–393

    PubMed  CAS  Google Scholar 

  21. Masurovsky EB, Peterson ER, Crain SM, Horwitz SB (1981) Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures. Brain Res 217(2):392–398

    Article  PubMed  CAS  Google Scholar 

  22. Masurovsky EB, Peterson ER, Crain SM, Horwitz SB (1985) Taxol effects on glia in organotypic mouse spinal cord-DRG cultures. Cell Biol Int Rep 9(6):539–546

    Article  PubMed  CAS  Google Scholar 

  23. Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94(3):293–304

    Article  PubMed  CAS  Google Scholar 

  24. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(5 Suppl 15):21–33

    Article  PubMed  CAS  Google Scholar 

  25. Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E et al (2002) Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2(1):54–58

    Article  PubMed  CAS  Google Scholar 

  26. Markman M (2003) Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2(2):141–146

    Article  PubMed  CAS  Google Scholar 

  27. Polomano RC, Bennett GJ (2001) Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2(1):8–14

    Article  PubMed  CAS  Google Scholar 

  28. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D et al (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7(5):1192–1197

    PubMed  CAS  Google Scholar 

  29. Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD (2004) Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 127(Pt 3):671–679

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Nazionale dei Tumori, Milan, Italy

    Caraceni Augusto, Martini Cinzia, Cresta Sara, Gianni Luca & Vidmer Scaioli

  2. Clinical Neurophysiology, Istituto Nazionale Neurologico C.Besta, Via Celoria 11, 20133, Milan, Italy

    Miccoli Pietro, Curzi Sergio & Vidmer Scaioli

Authors
  1. Caraceni Augusto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miccoli Pietro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martini Cinzia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Curzi Sergio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cresta Sara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gianni Luca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vidmer Scaioli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vidmer Scaioli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Augusto, C., Pietro, M., Cinzia, M. et al. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings. J Neurooncol 86, 89–99 (2008). https://doi.org/10.1007/s11060-007-9438-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-007-9438-8

Keywords

Search

Navigation